You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Recurrence-Free Survival

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Prognostic Factors Affecting Recurrence and Disease-Free

Recruiting
  • Rectal Cancer
  • curative surgery for cancer rectum
  • Qinā, Egypt
    Qena Faculty of Medicine, South Valley University Hospitals
Oct 21, 2023

Esophageal Cancer Trial in Shanghai (Propofol-based total intravenous anesthesia, Sevoflurane intravenous anesthesia)

Recruiting
  • Esophageal Cancer
  • Propofol-based total intravenous anesthesia
  • Sevoflurane intravenous anesthesia
  • Shanghai, China
    Shanhai Chest Hospital
Aug 26, 2021

Disease-free Survival of High-risk Head-neck Cutaneous Squamous

Active, not recruiting
  • Carcinoma, Squamous Cell
  • +5 more
  • Treatment
  • Maastricht, Netherlands
  • +1 more
Apr 26, 2023

Prostate Cancer, Salvage Radiotherapy, Biochemical Recurrence Trial (triptorelin, goserelin, leuprorelin)

Not yet recruiting
  • Prostate Cancer
  • +4 more
  • triptorelin, goserelin, leuprorelin
  • (no location specified)
Mar 10, 2023

T1 Squamous Cell Carcinomas of the Lip

Active, not recruiting
  • Lip
  • +9 more
    • Nijmegen, Gelderland, Netherlands
    • +2 more
    Nov 2, 2022

    Event-free Survival, Overall Survival, Local-recurrence Free Survival Trial in Beijing (Cisplatin)

    Completed
    • Event-free Survival
    • +3 more
    • Beijing, Beijing, China
      Peking University People's Hospital
    Jan 2, 2021

    PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer

    Recruiting
    • Immune Checkpoint Inhibitors
    • +9 more
    • Radiotherapy for targeted lesions and PD-1 antibody
    • Beijing, Beijing, China
      Lei Li
    Apr 1, 2022

    Liver Metastasis, Colon Cancer Trial in United Kingdom (Icosapent Ethyl, Placebo)

    Recruiting
    • Liver Metastasis
    • Colon Cancer
    • Icosapent Ethyl
    • Placebo
    • Oxford, Oxfordshire, United Kingdom
    • +12 more
    Nov 7, 2022

    The HELPP Score: A Pretreatment Score to Predict Survival in

    Not yet recruiting
    • Pancreatic Adenocarcinoma
      • Vienna, Austria
        Department of General Surgery, Division of Visceral Surgery, Med
      Feb 21, 2023

      Circumferential Resection Margin, Intraoperative Perforation of Rectum, Local Recurrence of Malignant Tumor of Rectum Trial in

      Recruiting
      • Circumferential Resection Margin
      • +4 more
      • neoadjuvant chemoradiotherapy
      • Beijing, Beijing, China
        Beijing Chaoyang Hospital
      Feb 4, 2021

      Meningioma, Meningioma Atypical, Anaplastic Meningioma Trial in Rome (Biological biomarker assessment)

      Recruiting
      • Meningioma
      • +2 more
      • Biological biomarker assessment
      • Rome, Italy
        Fondazione Policlinico Universitario A. Gemelli IRCCS
      Mar 29, 2023

      Renal Cell Carcinoma, Neoadjuvant Trial (Axitinib plus Toripalimab, radical nephrectomy)

      Not yet recruiting
      • Renal Cell Carcinoma
      • Neoadjuvant
      • Axitinib plus Toripalimab
      • radical nephrectomy
      • (no location specified)
      Feb 12, 2023

      3 Year Recurrence Free Survival in Ultra-low-risk Endometrial

      Not yet recruiting
      • Endometrial Cancer
      • no lymph node dissection
      • (no location specified)
      Jan 12, 2020

      Pancreatic Cancer Recurrence in the Netherlands

      Recruiting
      • Pancreatic Ductal Adenocarcinoma
      • +3 more
        • Utrecht, Netherlands
          UMC Utrecht
        Feb 1, 2023

        Metastatic Prostate Cancer Trial (Darolutamide, Radium-223)

        Not yet recruiting
        • Metastatic Prostate Cancer
        • (no location specified)
        Mar 6, 2023

        Recurrent Cervical Carcinoma, Radiotherapy, Epidermal Growth Factor Receptor Trial in Beijing (Combination of nimotuzumab and

        Recruiting
        • Recurrent Cervical Carcinoma
        • +6 more
        • Combination of nimotuzumab and radiotherapy
        • Beijing, Beijing, China
          Lei Li
        Dec 18, 2020

        to Explore Whether the Adjuvant Therapy of Metronomic Capecitabine Could Improve the Disease-free Survival of Locoregionally

        Recruiting
        • to Explore Whether the Adjuvant Therapy of Metronomic Capecitabine Could Improve the Disease-free Survival of Locoregionally Advanced Hypopharyngeal Carcinoma
        • Capecitabine 500Mg Oral Tablet
        • Shanghai, China
          Eye & ENT Hospital, Fudan University
        Jul 2, 2023

        Crestal Bone Loss, Survival Rate Trial in Cairo (placement of dental implants)

        Completed
        • Crestal Bone Loss
        • Survival Rate
        • placement of dental implants
        • Cairo, Egypt
          Ain Shams University
        Oct 21, 2023

        Radiotherapy Combined With EGFR-TKI for Stage III EGFR Mutant

        Completed
        • The Primary Study Metric is Progression-free Survival (PFS)
          • (no location specified)
          Jun 28, 2023

          Improving Liver Transplant-free Survival in Acute Decompensation

          Not yet recruiting
          • Decompensated Cirrhosis
          • No intervention
          • New Delhi, Delhi, India
            Institute of Liver & Biliary Sciences
          Jul 12, 2023

          Overall Survival, Progression-free Survival, Cost Trial (Microwave Ablation)

          Completed
          • Overall Survival
          • +2 more
          • Microwave Ablation
          • (no location specified)
          Apr 1, 2023

          Colonic Tumors, Tumor Recurrence, Local Trial

          Completed
          • Colonic Neoplasms
          • Neoplasm Recurrence, Local
            • (no location specified)
            Jul 25, 2022

            Rectal Tumors, Tumor Recurrence, Local Trial

            Completed
            • Rectal Neoplasms
            • Neoplasm Recurrence, Local
              • (no location specified)
              Jul 25, 2022

              Cell-free DNA From Junction of Hepatitis B Virus Integration in

              Active, not recruiting
              • Hepatocellular Carcinoma
                • Taipei, Taiwan
                  National Taiwan University Hospital
                Apr 10, 2023

                Bladder Cancer, Bladder Urothelial Carcinoma Trial in Toronto (re-TURBT, 6 weeks BCG instillation)

                Terminated
                • Bladder Cancer
                • Bladder Urothelial Carcinoma
                • re-TURBT
                • 6 weeks BCG instillation
                • Toronto, Ontario, Canada
                  University Health Network
                Apr 12, 2022